UBS upgrades TransDigm on margin expansion, capital deployment

Investing.com
25 Feb

Investing.com -- UBS upgraded TransDigm Group Inc, now rated "Buy" from "Neutral," on stabilised aftermarket growth, margin expansion, and increased capital deployment.

The bank forecasts aftermarket growth between 10 and 11%, easing concerns of further deceleration. It also projects EBITDA margins to expand by 100 basis points per year, above consensus estimates of 40-60 basis points, while still conservative compared to historical trends.

“TransDigm is a compounder of earnings organically and inorganically, with a recurring and often sole-source business model. A more M&A friendly environment could be further upside to our numbers,” analyst said.

UBS noted that TransDigm's net leverage of 5X, within its 5-7X target range, could result in $12 billion in available capital by year-end and $24 billion by fiscal 2027. 

The price target was raised to $1,595 from $1,502, reflecting higher EBITDA assumptions and a revised 21.0X 5-8 quarter EV/EBITDA multiple.

“We expect aftermarket growth to stabilize and accelerate from F1Q, with above-consensus margin expansion and the potential for a step-up in capital deployment,” analyst at UBS said.

Related Articles

UBS upgrades TransDigm on margin expansion, capital deployment

Bank of England policymakers at odds over pace of interest rate cuts

Palliser asks Rio Tinto to seek Australian shareholder vote on dual listing

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10